StockData
MapLight Therapeutics, Inc. logo

MapLight Therapeutics, Inc. (MPLT) company profile

MPLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$6.57−0.33 (-4.78%)

Close on Nov 17, 2026Market cap $304.70MP/E –Yield –

About MapLight Therapeutics

Pharmaceutical Preparations, SIC 2834

MapLight Therapeutics is a clinical-stage biopharmaceutical company that develops circuit-specific therapies for debilitating central nervous system disorders. The company operates a discovery platform to identify neural circuits causally linked to diseases and target those circuits for therapeutic modulation. Its lead product candidate is ML-007C-MA, a fixed-dose combination combining a muscarinic agonist with a peripherally acting anticholinergic agent. Its development programs serve individuals suffering from psychiatric and neurological conditions, specifically patients with schizophrenia and Alzheimer's disease psychosis.

The organization's operations include multiple clinical studies evaluated in healthy participants and patients across Phase 1 and Phase 2 clinical trials. Geographically, the company is incorporated in Delaware and conducts its business within the United States. MapLight Therapeutics maintains its principal executive offices and headquarters in Redwood City, California.

Summary of the business section of MapLight Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
MapLight Therapeutics, Inc.
Headquarters
Redwood City, CA
Address
800 Chesapeake Drive 94063
Phone
(650) 839-4360
Employees
133, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
RSM US LLP, Boston, Massachusetts

Stock & identifiers

Ticker
MPLT
Exchange
Nasdaq
IPO date
Oct 27, 2025
Shares outstanding
46M, Aug 7, 2026
Filer category
<br>Emerging growth company
SEC CIK
1770069
CUSIP
56565P103
ISIN
US56565P1030
FIGI
BBG01JZ5DBQ0
Share class FIGI
BBG01JZ5DBS8
EIN
83-2163243

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Christopher A. KroegerChief Executive Officer, Director1,297,099
Anatol KreitzerChief Discovery Officer168,678
Jonathan GillisCAO and Interim CFO142,315
James Woodruff LillieChief Scientific Officer198,597
Erin Pennock FoffChief Medical Officer296,906
Kristopher HansonGeneral Counsel128,024
Vishwas SetiaChief Financial Officer356,256
Troy CoxDirector23,484
George PavlovDirector28,932
Martin BablerDirector7,864
Maria C. WalkerDirector62,703
Timothy John GarnettDirector67,581
Nanna Liebach LuneborgDirector3,932
Robert C. MalenkaDirector348,138
James D. TrenkleDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Christopher A. Kroeger, M.D.
President and Chief Executive Officer
$655.25K$12.30M$12.32M$331.00K$19.33K$25.62M+192%
Vishwas Setia
Chief Financial Officer
$432.29K$3.20M$2.37M$183.00K$19.15K$6.20M+102%
Erin Pennock Foff, M.D., Ph.D.
Chief Medical Officer
$531.00K$2.87M$2.64M$194.00K$20.85K$6.25M+127%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 24, 2025ListingRegistration of securities on an exchange (Form 8-A)
Mar 22, 2019Name changeName changed from Alvarado Therapeutics, Inc. to MapLight Therapeutics, Inc.

See a number that looks wrong?